• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Use of radioactive copper (67Cu) makes effective and efficient cancer treatment possible

Research Project

Project/Area Number 20K08090
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 52040:Radiological sciences-related
Research InstitutionSuzuka University of Medical Science

Principal Investigator

Iida Yasuhiko  鈴鹿医療科学大学, 薬学部, 教授 (60252425)

Project Period (FY) 2020-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2021: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2020: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords67Cu / 核医学治療 / がん / マウス / 神経内分泌腫瘍 / somatostatin / 放射性薬剤 / 放射性銅 / somatostatin受容体 / ペプチド化合物 / Cu-67 / 内用放射線療法 / がん治療
Outline of Research at the Start

本研究では、β-線のエネルギーが高ければ腫瘍の大小にかかわらず治療効果が高いのか、腫瘍サイズに応じた最適のエネルギーが存在するのか、あるいはエネルギーの低いβ-線が効率的な治療に結びつくのか、を明らかにするため、1) 67Cu標識薬剤を設計・合成し、担がんモデルマウスを用いて分布動態、抗腫瘍効果を評価する、2) 腫瘍サイズと67Cu標識薬剤の治療効果の関係を明らかにする、3) 90Y標識薬剤の治療効果と比較検討する、の3段階で実験を実施する。

Outline of Final Research Achievements

Copper-67 is an attractive radionuclide for nuclear medicine therapy, which has an emitted β-particle energy suitable for applying to small tumors (0.392 MeV) and a physical half-life of 61.8 hours long enough to damage them.
In this study, we prepared a novel somatostatin derivative, ToDBTTATE, labeled with 67Cu, and evaluated its potential for cancer therapy in mice bearing AR42J rat pancreatic tumor cells. 67Cu-ToDBTTATE showed high accumulation in the tumor and substantial tumor size reduction was observed in all mice treated with 67Cu-ToDBTTATE. Furthermore, mice with tumors of various sizes were prepared and the differences in the therapeutic effect of 67Cu-ToDBTTATE on the tumor size were examined to clarify the relationship between tumor size and the therapeutic effects of 67Cu-ToDBTTATE. As a result, a tumor growth constricting effect was observed in all mice compared with the control, but some tumor growth was observed in the group with a tumor size of more than 800 mm3.

Academic Significance and Societal Importance of the Research Achievements

国内で内用放射線療法に用いられている4核種以外にも治療での有効性が期待されるRIは多数存在する。この中で67Cuはβ-線のエネルギーが低く、十分な治療効果が得られるか不明である一方、大量投与が可能で、がん組織の状態によっては効果的・効率的な治療を実現することが期待できる。様々な腫瘍に対し67Cu標識薬剤の治療効果を検証することで低エネルギーβ-線の有効性が明らかになれば、様々なエネルギー、半減期を有する治療用RIの研究発展へとつながると考えられる。さらにこれらの成果は、患者の病態に合わせた効果的・効率的な治療、個別化医療に貢献することが期待される。

Report

(5 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (6 results)

All 2023 2022 2021 2020

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 2 results) Presentation (3 results)

  • [Journal Article] Efficacy of nuclear medicine therapy with 67CuCl2 in mice bearing LS180 colon cancer.2023

    • Author(s)
      Y. Fujisawa, Y. Sugiura, H. Haba, A. Nambu, Y. Shigekawa, X. Yin, Y. Magata, Y. Iida
    • Journal Title

      RIKEN Accelerator Progress Report

      Volume: 56 Pages: 156-156

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Effect of tumor size on the therapeutic effect of 67Cu-labeled compounds targeting the somatostatin receptor2021

    • Author(s)
      Y. Fujisawa, H. Haba, A. Nambu, Y. Shigekawa, Y. Wang, X. Yin, Y. Magata, Y. Iida
    • Journal Title

      RIKEN Accelerator Progress Report

      Volume: 55

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Usability of 67Cu as a therapeutic radioisotope for peptide receptor radionuclide therapy.2020

    • Author(s)
      Y. Fujisawa, H. Haba, Y. Magata, Y. Iida
    • Journal Title

      RIKEN Accelerator Progress Report

      Volume: 54

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Presentation] 新規アミノ酸ATSMaaのLAT1標的薬剤としての可能性2022

    • Author(s)
      飯田靖彦、藤澤豊
    • Organizer
      日本薬学会第142年会
    • Related Report
      2022 Research-status Report
  • [Presentation] 67Cuを用いた効果的・効率的ながん治療の可能性2021

    • Author(s)
      飯田靖彦
    • Organizer
      核医学診断・治療のためのRI利用推進シンポジウム― 64Cu・67Cu:核種製造と治療薬創製の展望 ―
    • Related Report
      2021 Research-status Report
  • [Presentation] Cu-67標識新規ソマトスタチン誘導体を用いた神経内分泌腫瘍に対する腫瘍抑制効果の評価2020

    • Author(s)
      藤澤豊、飯田靖彦
    • Organizer
      第60回日本核医学会総会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi